Clinical Trial Update: Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sotatercept for chemotherapy-induced anemia in metastatic breast cancer was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Anemia

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy Induced Anemia | Phase 2 | Status: TERMINATED | Results posted: 2023-09-13